Detection of triazole resistance among Candida species by matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF MS)

Medical Mycology

Volumn 53, Issue 7, 2015, Pages 736-742

  Saracli, Mehmet A ^a   Fothergill, Annette W ^b   Sutton, Deanna A ^b   Wiederhold, Nathan P ^b  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Candida; MALDI TOF MS; Resistance; Susceptibility testing

Indexed keywords

FLUCONAZOLE; POSACONAZOLE; TRIAZOLE; VORICONAZOLE; ANTIFUNGAL AGENT; TRIAZOLE DERIVATIVE;

ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA TROPICALIS; COMPARATIVE STUDY; DRUG DETERMINATION; DRUG SENSITIVITY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NONHUMAN; REPRODUCIBILITY; CANDIDA; CLASSIFICATION; DRUG EFFECTS; EVALUATION STUDY; HUMAN; ISOLATION AND PURIFICATION; MASS SPECTROMETRY; MICROBIAL SENSITIVITY TEST; PROCEDURES;

ANTIFUNGAL AGENTS; CANDIDA; DRUG RESISTANCE, FUNGAL; HUMANS; MICROBIAL SENSITIVITY TESTS; REPRODUCIBILITY OF RESULTS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TRIAZOLES;

EID: 84941211665     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.1093/mmy/myv046     Document Type: Article

References (24)

1. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005; 49: 3640-3645.
2. Murali S, Langston A. Advances in antifungal prophylaxis and empiric therapy in patients with hematologic malignancies. Transpl Infect Dis 2009; 11: 480-490.
3. Arendrup MC. Epidemiology of invasive candidiasis. Curr Opin Crit Care 2010; 16: 445-452.
4. Falagas ME, Roussos N, Vardakas KZ. Relative frequency of albicans and the various non-Albicans Candida spp among candidemia isolates from inpatients in various parts of the world: a systematic review. Int J Infect Dis 2010; 14: e954-966.
5. Pfaller M, Neofytos D, Diekema D et al. Epidemiology and outcomes of candidemia in 3648 patients: data from the Prospective Antifungal Therapy (PATH Alliance R-) registry, 2004-2008. Diagn Microbiol Infect Dis 2012; 74: 323-331.
6. Pfaller MA, Messer SA, Moet GJ et al. Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole ant ifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008-2009). Int J Antimicrob Agents 2011; 38: 65-69.
7. NegriM, Silva S, Henriques Met al. Insights into Candida tropicalis nosocomial infections and virulence factors. Eur J Clin Microbiol Infect Dis 2012; 31: 1399-1412.
8. Pfaller MA, Jones RN, CastanheiraM. Regional data analysis of Can dida non-Albicans strains collected in United States medical sites over a 6-year period, 2006-2011. Mycoses 2014; 57: 602-611.
9. Muñoz P, Giannella M, Fanciulli C et al. Candida tropicalis fungaemia: incidence, risk factors and mortality in a general hospital. Clin Microbiol Infect 2011; 17: 1538-1545.
10. Kontoyiannis DP, Vaziri I, Hanna HA et al. Risk factors for Candida tropicalis fungemia in patients with cancer. Clin Infect Dis 2001; 33: 1676-1681.
11. Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID Eu ropean Committee for Antimicrobial Susceptibility Testing (EUCAST). EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. Clin Microbiol Infect 2008; 14: 3 98-405.
12. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. M27-S4. Fourth informational supplement. Wayne, PA: Clinical Laboratory Standards Institute, 2012.
13. Revankar SG,Kirkpa trick WR,McAtee RK,et al. Interpretation of trailing endpoints in antifungal susceptibility testing by the National Committee for Clinical Laboratory Standards method J Clin Microbiol 1998 36: 153-156.
14. Lass-Flörl C, Mayr A, Perkhofer S et al. Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. Antimicrob Agents C hemother 2008; 52: 3637-3641.
15. Dhiman N, Hall L, Wohlfiel SL et al. Performance and cost analysis of matrix-Assisted laser desorption ionization-time of flight mass spectrometry for routine identif ication of yeast. J Clin Microbiol 2011; 49: 1614-1616.
16. Vella A, De Carolis E, Vaccaro L et al. Rapid Antifungal Susceptibility Testing by Matrix-Assisted Laser Desorption Ionization Time-of-Flight Mass Spectrometry Analysis. J Clin Microbiol 2013; 51: 2964-2969.
17. Marinach C, Alanio A, Palous M et al. MALDI-TOF MS-based drug susceptibility testing of pathogens: The example of Ca ndida albicans and fluconazole. Proteomics 2009; 9: 4627-4631.
18. Rogers PD, Vermitsky JP, Edlind TD et al. Proteomic analysis of experimentally induced azole resistance in Candida glabrata. J Antimicrob Chemother 2006; 58: 434-438.
19. Oviãno M, Fernández B, Fernández A et al. Rapid detection of enterobacteriaceae producing extended spectrum betalactamases directly from positive blood culture s by Matrix-Assisted Laser-Desorption-Ionization Time-of-Flight Mass Spectrometry (MALDI-TOF-MS). Clin Microbiol Infect 2014; 20: 1146-1157.
20. Johansson A, Nagy E, Soki J. Instant screening and verifica tion of carbapenemase activity in B. fragilis in positive blood culture, using matrix-Assisted laser desorption Ionization-time of flight mass spectrometry (MALDI-TOF-MS). J Med Microbiol 2014; 63: 1105-1110.
21. Pfaller MA, Diekema DJ. Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012. J Clin Microbiol 2012; 50: 2846-2856.
22. De Carolis E, Vella A, FlorioARet al.Use of matrix-Assisted laser desorption ionization-time of flight mass spectrometry (MALDITOF MS) for caspofungin susceptibility testing of Candida and Aspergillus species. J Clin Microbiol 2012; 50: 2479-2483.
23. Arnold RJ, Reilly JP. Fingerprint matching of E. coli strains with matrix-Assisted laser desorption/ionization time-of-flight mass spectrometry of whole cells using a modif ied correlation approach. Rapid Commun Mass Spectrom 1998; 12: 630-636.
24. Espinel-Ingroff A, Pfaller MA, Bustamante B et al. Multilaboratory study of epidemiological cutoff values for azoleresistance detection of eight Candida spp. to fluconazole, posaconazole, and voriconazole. Antimicrob Agents Chemother 2014; 58: 2006-2012.